Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in: memo - Magazine of European Medical Oncology 3/2012

01.09.2012 | editorial

News from the Neuro-Oncology front

verfasst von: Silvia Hofer, MD, Christine Marosi, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Excerpt

Neuro-Oncology, a fast evolving field in oncology, is gaining momentum in the molecular understanding of different brain tumor entities, a fact that might hopefully result in more potent treatment strategies. …
Vorheriger Artikel ASH 2011: “Real generosity toward the future lies in giving all to the present”
Nächster Artikel ASH 2011—Hodgkin’s disease and the high grade lymphomas
Literatur
1.
Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedCrossRef
2.
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Onol. 2009;27(35):5874–80.CrossRef
3.
Van Den Bent M J, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized european organisation for research and treatment of cancer phase III trial. J Clin Onol. 2006;24:2715–22.CrossRef
4.
Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixedanaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–14.PubMedCrossRef
Metadaten
Titel
News from the Neuro-Oncology front
verfasst von
Silvia Hofer, MD
Christine Marosi, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0031-2

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe

short review

Brief update on recent developments in CML

short review

Primary central nervous system lymphoma: update and current approach

short review

Treating T-cell lymphoma: is there a light at the end of the tunnel?

short review

Clinically useful biomarkers in neurooncology

short review

Follow-up care for head and neck cancer patients

short review

Advanced neuroimaging techniques for diagnosis and treatment evaluation in neuro-oncology